MoleculeMind
AI NativeAI-Driven Protein Discovery and Design.
Est 2022|Raised $14.8M
AI-Driven Protein Discovery and Design.
Published Aug 14, 2026
AI-for-biology platform outcomes vary; common procurement patterns include initial pilot projects followed by expansion contingent on repeatable experimental validation.
| Starting Price | Not public (likely enterprise/partnership) | Not public (enterprise) | Not public (partnership/enterprise) |
| Primary Focus | Protein prediction, optimization, and design (per vendor materials) | Enterprise computational chemistry and collaboration workflows | Structure-based small-molecule hit discovery via AI screening/partner model |
| Public Evidence / Positioning | Vendor and press messaging emphasize protein design platform capabilities; limited independent public validation found | Established enterprise presence and broad toolchain for computational chemistry and drug discovery projects | Known for small-molecule AI screening and partnership agreements |
| Key Limitations | Limited public technical benchmarks and independent customer reviews in accessible sources | May be more oriented to computational chemistry than de novo protein generation | Not focused on protein-design workflows; modality mismatch for biologics programs |
—
Based on public materials and press coverage, MoleculeMind’s primary positioning is a platform-oriented offering focused on protein design and optimization. Schrödinger is typically selected by organizations seeking a broad enterprise computational chemistry platform with collaboration features, while Atomwise is often cited in the context of AI-enabled small-molecule discovery and screening partnerships. The appropriate vendor depends on modality (protein vs small molecule), integration needs, and validation requirements.